Use of upadacitinib for recalcitrant oral erosive lichen planus
Open Access
- 31 March 2025
- journal article
- case report
- Published by Elsevier in JAAD Case Reports
- Vol. 60, 167-169
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Oral Lichen Planus: A Narrative Review Navigating Etiologies, Clinical Manifestations, Diagnostics, and Therapeutic ApproachesJournal of Clinical Medicine, 2024
- Oral Lichen Planus Successfully Treated With UpadacitinibJournal Of Drugs In Dermatology, 2024
- Upadacitinib: Mechanism of action, clinical, and translational scienceClinical and Translational Science, 2023
- CD8+ tissue-resident memory T cells induce oral lichen planus erosion via cytokine networkeLife, 2023
- The Use of Janus Kinase Inhibitors for Lichen Planus: An Evidence-Based ReviewJournal of Cutaneous Medicine and Surgery, 2023
- Successful treatment of erosive lichen planus with Upadacitinib complicated by oral squamous cell carcinomaSage Open Medical Case Reports, 2023
- Treatment of Oral Erosive Lichen Planus With UpadacitinibJAMA Dermatology, 2022
- Immune mechanisms in oral lichen planusOral Diseases, 2022
- Alleviation of erosive oral and esophageal lichen planus by the JAK1 inhibitor upadacitinibJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2021